Lv5
1430 积分 2025-05-06 加入
Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma
7天前
已完结
Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma
27天前
已完结
Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma
27天前
已完结
Does chemotherapy regimen matter for first-line immunochemotherapy in low PD-L1-expressing esophageal squamous cell carcinoma? A systemic review and meta-analysis
1个月前
已完结
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
1个月前
已完结
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
1个月前
已完结
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
1个月前
已完结
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
1个月前
已完结
304P Sintilimab consolidation therapy following concurrent chemoradiotherapy in unresectable stage III NSCLC: Primary results from the prospective CONSIST trial
1个月前
已关闭
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
1个月前
已完结
皖公网安备34019202002308
